SCHEMBL26430057

SCHEMBL26430057

C/C=C/CN1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ CHRM2 P08172 1/20 0.45
▸ CHRM4 P08173 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ CHRM3 P20309 1/20 0.45
▸ DDB1 Q16531 1/20 0.41
▸ CRBN Q96SW2 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ TGM2 P21980 2/20 0.40
▸ F13A1 P00488 1/20 0.40
▸ ABCB1 P08183 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14165640 0.84 USP2 (0.45) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL14604907 0.84 USP2 (0.45) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL14165639 0.84 USP2 (0.45) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL17532546 0.84 USP2 (0.45) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL1498905 0.83 USP2 (0.50) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL7447764 0.82 USP2 (0.49) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL1498991 0.82 USP2 (0.43) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL30418583 0.82 USP2 (0.43) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL2086130 0.82 USP2 (0.43) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL1498893 0.82 USP2 (0.43) USP2SMN1; SMN2CHRM2CHRM4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023067353-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 — — WO disclosed
Send feedback